CD4+ T cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapy

Cancer patients often receive a combination of antibodies targeting programmed death-ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen-4 (CTLA4). We conducted a window-of-opportunity study in head and neck squamous cell carcinoma (HNSCC) to examine the contribution of anti-CTLA4 to anti-PD-L1 ther...

Full description

Saved in:

Bibliographic Details
Published in:	Immunity (Cambridge, Mass.) Mass.), 2024-03, Vol.57 (3), p.541-558.e7
Main Authors:	Franken, Amelie, Bila, Michel, Mechels, Aurelie, Kint, Sam, Van Dessel, Jeroen, Pomella, Valentina, Vanuytven, Sebastiaan, Philips, Gino, Bricard, Orian, Xiong, Jieyi, Boeckx, Bram, Hatse, Sigrid, Van Brussel, Thomas, Schepers, Rogier, Van Aerde, Cedric, Geurs, Sarah, Vandecaveye, Vincent, Hauben, Esther, Vander Poorten, Vincent, Verbandt, Sara, Vandereyken, Katy, Qian, Junbin, Tejpar, Sabine, Voet, Thierry, Clement, Paul M., Lambrechts, Diether
Format:	Article
Language:	English
Subjects:	B7-H1 Antigen - genetics CD4+ T helper 1 cells CD4-Positive T-Lymphocytes CD8-Positive T-Lymphocytes checkpoint blockade CTLA-4 Antigen Head and Neck Neoplasms - drug therapy head and neck squamous cell carcinoma Humans immunotherapy mechanisms of response peripheral blood mononuclear cells single-cell omics Squamous Cell Carcinoma of Head and Neck T cell trafficking Tumor Microenvironment tumor-draining lymph node
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!